The life sciences industry thrives on innovation, so it’s no surprise that COVID-19 is rapidly driving inventive analytics solutions to address key challenges posed by the crisis. In this session, we’ll explore the impact of the pandemic on pharmaceutical manufacturers and the resulting acceleration of digitization as the industry responds and adapts.

Life sciences companies are taking advantage of digital health and virtual trial methodologies to mitigate delays on clinical research. They are using epidemiological modeling to study and predict the potential for using real-world data to gather evidence for COVID-19 therapies. They are evolving their sales and marketing strategies to optimize the overnight shift to digital channels to connect with prescribers. Finally, SAS experts will share perspective on lessons learned and the road ahead.

Confirmed Speakers

• Sherrine Eid, Principal Industry Consultant - SAS

• Patrick Homer, Advisory Industry Consultant - SAS

• Mark Lambrecht, Director - SAS

• Matt Becker, Advisory Industry Consultant - SAS

For more information, please contact:

Ryan Butt

Director, Partnerships & Events

Tel.: 604-669-9909 ext. 104

rbutt@lifesciencesbc.ca